SYNX Pharma Inc.

Capitalizing on its proprietary antibody-based expertise, SYN•X Pharma Inc.’s vision is to be a world leader in the discovery and development of innovative diagnostics and therapeutic targets for use in preventative medicine and disease management. The company is currently developing risk-assessment and diagnostic tests for diabetes, heart failure and Alzheimer’s Disease. SYN•X has completed the development of the StrokepanelTM, a stroke diagnostic test. SYN•X is a research and development company. Manufacturing, sales and distribution of the products will be undertaken by strategic partnerships in the Pharmaceutical and Biotechnology Industries. In October 1999, SYN•X exclusively licensed Strokepanel™, a rapid format, point-of-care, stroke diagnostic test, to Genzyme Diagnostics for co-development, manufacture, and global distribution. Genzyme's customer base includes the top seven diagnostic companies that cover approximately 80% of the global, in-vitro diagnostic market. SYN•X receives $15 million in milestone payments, as well as double-digit sales royalties. In February 2000, SYN•X entered into a Clinical Investigation Agreement with a multi-national, Japanese pharmaceutical company that is developing a new stroke drug. SYN•X's SMART S-100 ELISA Test Kit will determine concentrations of S-100 in the pharmaceutical company's clinical blood samples in order to help prove the efficacy of their therapeutic. In 2000, SYN•X entered into Pre-Clinical Investigation Agreements with two multi-national pharmaceutical companies

Activity:

- Research & Development

Product / Technology type(s) covered:

- Bio
- Diagnostics
- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: